CSL,VarmX deal aligns with R&D strategy, offers earnings upside, Morgan Stanley says
Morgan Stanley says the agreement between CSL CSL.AX and VarmX aligns with the biotech giant's recalibrated R&D strategy, offering potential for earnings and valuation upside
Brokerage expects potential mid-single-digit EPS accretion over long-term, with potential valuation upside of about A$19/share
Reduces PT on CSL to A$285 from A$291, to reflect Aussie dollar appreciation against the U.S dollar AUD/
Eleven of 16 analysts rate the stock "buy" or higher, five rate "hold"; their median PT is A$294.21, according to data compiled by LSEG
Stock YTD is down 29.2%
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

US-Iran Tensions Heat Up Again, Brent Crude Prices Return Above $100

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Navitas Stock’s AI Data Center Pivot: Up 88% YTD—Is NVTS Stock Still a Buy?

Tradingkey






